Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 196

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 196
---
 such agreement on July 23, 2024, the Predecessor became a new wholly owned subsidiary of the Company, and as determined by the Company’s
board of directors. Following the closing of the Share Exchange agreement, the Company’s Board of Directors determined to discontinue
all of the Company’s prior activities and efforts in the development and activation of the clinical decision-making support system
which constituted the business of the Successor prior to the closing of the stock exchange agreement, and to focus on the development
of the acquired LipoVation’s business, refer to Note 3.

| b. | Liquidity and management plans: |

The Company
is in the research and development (R&D) stage and, as such, has not generated any revenues from its current operations. The Company’s
activities are primarily funded through investment. As of December 31, 2024, the Company reported an accumulated deficit of $11,513.

To support
its operations and advance its development programs, the Company intends to continue securing investments. Management anticipates that
additional capital will be necessary to fund its ongoing R&D activities and to explore opportunities for acquiring healthcare or healthcare-related
technologies. However, there are currently no binding commitments for further investment, and there can be no assurance that the Company
will secure the required capital on commercially reasonable terms, or at all.

If sufficient
investment cannot be obtained, the Company may need to implement cost-cutting measures, scale back its R&D activities, or delay certain
development programs. Despite these potential challenges, management and the board of directors believe that the Company’s existing
financial resources will be sufficient to sustain its planned operations for at least the next twelve months.

The consolidated
financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts
and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

<div align='center'>F-8</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 1 – GENERAL (Cont.)

To date, Predecessor
has not generated any revenue from its current operations and therefore is dependent upon external sources for financing its operations.
As of July 23, 2024, and December 31, 2023, the Predecessor had an accumulated deficit of $3,343 and $1,922, respectively Furthermore,
the Company intends to continue to finance the